Stereoselective synthesis of nucleosides and 4'-thionucleoside analogs from acyclic substrates

ORGN 55

Benoit Cardinal-David, cardinb@ircm.qc.ca1, Michel Prévost1, Daniel Chapdelaine2, Marc Gagnon3, Isabelle Tamburlin4, and Yvan Guindon, yvan.guindon@ircm.qc.ca1. (1) Chemistry Department (Université de Montréal), Institut de recherches cliniques de Montreal, 110, avenue des Pins West, Montréal, QC H2W 1R7, Canada, (2) Department of Chemistry, Université du Québec à Montréal, C.P. 8888, Succ. Centre-Ville, Montréal, QC H3C 3P8, Canada, (3) Department of Medicinal Chemistry, Merck Frosst Canada & Co, 16711, Trans Canada Hwy, Kirkland, QC H9H 3L1, Canada, (4) Centre de Recherche en Oncologie Expérimentale Chimie Médicinale, Institut de Recherche Pierre FABRE, 3, Rue des Satellites Parc Technologique du Canal, BP94244, 31432 Toulouse Cedex 4 FRANCE, Toulouse, France
Nucleoside analogues are part of the most important biologically and pharmaceutically active class of compounds used for treating many cancers and viral infections. The emergence of virus resistance to these drugs and the need to control other viruses and cancers require that novel drugs be identified.

Herein, we present a new synthetic route to gain access to nucleosides and 4'-thionucleoside analogues from acyclic dithioacetals. The first step involves a diastereoselective base coupling leading to the formation of a thioaminal. This adduct can then be cyclized to give nucleoside analogues via displacement of the activated sulfide of the thioaminal (C4'-C1' cyclization mode). Alternatively, converting the C4' alcohol into a leaving group and employing the sulfur atom as a nucleophile allows the synthesis of 4'-thionucleosides (C1'-C4' cyclization mode).

Studies aimed at unraveling the reaction mechanisms involved will be presented as well as the scope and limitations of the reaction sequence.